Drugs / H3K27M-EIEs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07501156 | Mar 2026 → Dec 2029 expected | glioma | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H3K27M-EIEs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07501156 ↗ |
| Modality | Cell therapy | “anti-H3K27M EIE cells” NCT07501156 ↗ |
| Route | Intravenous | “via intravenous injection each time” NCT07501156 ↗ |